Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mammary Analogue Secretory Carcinoma | 1 | 2023 | 8 | 0.850 |
Why?
|
| Oropharyngeal Neoplasms | 5 | 2022 | 283 | 0.840 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2023 | 67 | 0.810 |
Why?
|
| Carcinoma | 1 | 2023 | 322 | 0.690 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2022 | 118 | 0.520 |
Why?
|
| Hemangiosarcoma | 2 | 2014 | 47 | 0.480 |
Why?
|
| Splenic Neoplasms | 1 | 2014 | 12 | 0.440 |
Why?
|
| Leukocytosis | 1 | 2014 | 48 | 0.430 |
Why?
|
| Thrombocytopenia | 1 | 2014 | 237 | 0.370 |
Why?
|
| Anemia | 1 | 2014 | 349 | 0.320 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2011 | 177 | 0.320 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 188 | 0.320 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2011 | 147 | 0.310 |
Why?
|
| Scleroderma, Systemic | 3 | 2016 | 130 | 0.290 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2019 | 873 | 0.280 |
Why?
|
| Lung | 2 | 2011 | 1575 | 0.250 |
Why?
|
| Fatal Outcome | 3 | 2014 | 376 | 0.240 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2005 | 27 | 0.230 |
Why?
|
| Influenza, Human | 1 | 2011 | 699 | 0.230 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 397 | 0.220 |
Why?
|
| Gingiva | 1 | 2023 | 12 | 0.210 |
Why?
|
| Gene Fusion | 1 | 2023 | 61 | 0.200 |
Why?
|
| Lymphatic Metastasis | 1 | 2023 | 453 | 0.190 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 793 | 0.180 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2023 | 236 | 0.180 |
Why?
|
| Translocation, Genetic | 1 | 2023 | 363 | 0.180 |
Why?
|
| Thrombosis | 1 | 2005 | 547 | 0.160 |
Why?
|
| Head and Neck Neoplasms | 2 | 2022 | 702 | 0.160 |
Why?
|
| Disease-Free Survival | 3 | 2016 | 972 | 0.150 |
Why?
|
| Fibroblasts | 3 | 2016 | 925 | 0.150 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 1391 | 0.140 |
Why?
|
| Deglutition Disorders | 1 | 2019 | 147 | 0.130 |
Why?
|
| Semaphorins | 1 | 2016 | 33 | 0.130 |
Why?
|
| Biomarkers, Tumor | 2 | 2023 | 1721 | 0.120 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 1492 | 0.120 |
Why?
|
| Hodgkin Disease | 1 | 2018 | 298 | 0.120 |
Why?
|
| Demography | 1 | 2016 | 247 | 0.120 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 1488 | 0.110 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 251 | 0.110 |
Why?
|
| HLA-DRB1 Chains | 1 | 2014 | 46 | 0.110 |
Why?
|
| Skin | 2 | 2010 | 553 | 0.110 |
Why?
|
| Protein Transport | 1 | 2016 | 390 | 0.110 |
Why?
|
| Chemoradiotherapy | 1 | 2015 | 130 | 0.110 |
Why?
|
| Middle Aged | 8 | 2019 | 29427 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 2197 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2018 | 825 | 0.110 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 49 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 592 | 0.100 |
Why?
|
| Prognosis | 3 | 2022 | 5085 | 0.100 |
Why?
|
| Quantitative Trait Loci | 1 | 2014 | 317 | 0.100 |
Why?
|
| Humans | 17 | 2023 | 134149 | 0.100 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 897 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 1317 | 0.090 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2011 | 23 | 0.090 |
Why?
|
| Genotype | 2 | 2016 | 2808 | 0.090 |
Why?
|
| Biocatalysis | 1 | 2011 | 37 | 0.090 |
Why?
|
| Breast Neoplasms | 2 | 2023 | 2771 | 0.090 |
Why?
|
| Male | 12 | 2019 | 66108 | 0.090 |
Why?
|
| RNA, Small Interfering | 2 | 2011 | 721 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 738 | 0.080 |
Why?
|
| Osteonectin | 1 | 2010 | 6 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 1343 | 0.080 |
Why?
|
| Pulmonary Fibrosis | 1 | 2010 | 112 | 0.080 |
Why?
|
| Cell Nucleus | 1 | 2011 | 691 | 0.070 |
Why?
|
| Adult | 7 | 2018 | 31976 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 2174 | 0.070 |
Why?
|
| Aged | 6 | 2019 | 21779 | 0.070 |
Why?
|
| Veterans | 2 | 2015 | 1785 | 0.060 |
Why?
|
| Fenretinide | 1 | 2005 | 10 | 0.060 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2005 | 63 | 0.060 |
Why?
|
| Catastrophic Illness | 1 | 2005 | 3 | 0.060 |
Why?
|
| HIV Infections | 1 | 2018 | 2075 | 0.060 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2005 | 20 | 0.060 |
Why?
|
| Vascular Neoplasms | 1 | 2005 | 34 | 0.060 |
Why?
|
| Female | 10 | 2019 | 71905 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 143 | 0.060 |
Why?
|
| Skin Ulcer | 1 | 2005 | 33 | 0.060 |
Why?
|
| Microcirculation | 1 | 2005 | 117 | 0.060 |
Why?
|
| Risk Factors | 2 | 2016 | 11179 | 0.050 |
Why?
|
| Tamoxifen | 1 | 2005 | 377 | 0.050 |
Why?
|
| Multiple Organ Failure | 1 | 2005 | 144 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 3488 | 0.050 |
Why?
|
| Pulmonary Artery | 1 | 2005 | 468 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2022 | 191 | 0.040 |
Why?
|
| Smoking | 2 | 2015 | 1136 | 0.040 |
Why?
|
| Transfection | 2 | 2011 | 1096 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2022 | 357 | 0.040 |
Why?
|
| Gene Expression | 2 | 2016 | 1621 | 0.040 |
Why?
|
| Gastrostomy | 1 | 2019 | 92 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2005 | 1612 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 79 | 0.030 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 128 | 0.030 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2016 | 18 | 0.030 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2016 | 12 | 0.030 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2016 | 25 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 150 | 0.030 |
Why?
|
| Silicon Dioxide | 1 | 2016 | 31 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2016 | 109 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 1854 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2002 | 1922 | 0.030 |
Why?
|
| Hospitals, Military | 1 | 2015 | 11 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 324 | 0.030 |
Why?
|
| Carcinogens | 1 | 2015 | 160 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 1764 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 3797 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2015 | 100 | 0.030 |
Why?
|
| China | 1 | 2014 | 296 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 675 | 0.030 |
Why?
|
| Hospitals, Veterans | 1 | 2015 | 364 | 0.030 |
Why?
|
| Cell Movement | 1 | 2016 | 918 | 0.030 |
Why?
|
| Alcoholism | 1 | 2015 | 253 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 1146 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2015 | 387 | 0.020 |
Why?
|
| Diet | 1 | 2019 | 1195 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2015 | 1599 | 0.020 |
Why?
|
| Sumoylation | 1 | 2011 | 40 | 0.020 |
Why?
|
| Incidence | 1 | 2019 | 3416 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 206 | 0.020 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2010 | 22 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2010 | 130 | 0.020 |
Why?
|
| Gene Knock-In Techniques | 1 | 2010 | 127 | 0.020 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2010 | 107 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5478 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2010 | 247 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 2561 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 546 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 1140 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2016 | 1620 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1331 | 0.020 |
Why?
|
| Fibrosis | 1 | 2010 | 463 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2015 | 17539 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2936 | 0.020 |
Why?
|
| Mice | 2 | 2016 | 19045 | 0.020 |
Why?
|
| Texas | 1 | 2015 | 3715 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 90 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 5213 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2015 | 3742 | 0.020 |
Why?
|
| Clone Cells | 1 | 2005 | 180 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 2539 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 3186 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2002 | 36 | 0.010 |
Why?
|
| Animals | 2 | 2016 | 36546 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 472 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2018 | 13077 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 774 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 4877 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 4806 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2002 | 2043 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2002 | 2136 | 0.010 |
Why?
|